Indicatrix has been shortlisted for an award at this year’s CPhI Pharma Awards in Frankfurt. The API Development Award looks for innovation in technologies, products, processes, and services for the development and manufacture of active pharmaceutical ingredients (APIs) including, but not limited to, synthesis, characterization, formulation, scale-up, software and database development, bulk manufacturing.
Since its inception in 2004, the CPHI Pharma Awards has celebrated cross-industry innovators making a contribution to driving the industry forward, though people, products and performance. The Awards welcomes entries from pharmaceutical and biopharmaceutical companies across the globe, engaged in the design, development, manufacture, production and distribution of both large and small molecule drug products. This year, over 181 entries were received across the 10 categories which span all aspects of the industry, from API Development, Manufacturing Technology & Equipment and Digital Innovation to the prestigious CEO of the Year Award. All entries are reviewed in extensive detail by the CPhI expert panel of 17 Jury Members, who collectively bring decades of expertise from big pharma, consultancy, regulatory, market intelligence and academia. Each entry receives a score from the Jury on specific criteria, which include; innovation, outcomes, features and purpose, problem-solving and competitive advantage. Top scoring entries in each category are shortlisted, and in the running to take home the trophy.
Dr Lina Mardiana was presented with the award for the best poster at the British Crystallographic Association spring meeting. Dr Mardiana presented her recent work on the development of ENaCt to facilitate the crystallisation of complex natural products.
Indicatrix Crystallography are proud to announce that we have been awarded an Innovate UK “Global Cooperation Feasibility Studies” grant to further develop our technical capabilities in Encapsulated Nanodroplet Crystallisation technology (ENaCt). This Innovate UK funding will support a number of ICX staff for an 3 month R&D project, focussed on next generation ENaCt single crystal growth and analysis, to expand our capacity to support drug development in the pharmaceutical sector.
“Innovate UK, the UK’s innovation agency, drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas. They connect businesses to the partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth. They fund business and research collaborations to accelerate innovation and drive business investment into R&D. Support is available to businesses across all economic sectors, value chains and UK regions. Innovate UK is part of UK Research and Innovation. For more information visit www.innovateuk.ukri.org”
We’re excited to have received a graduate internship grant from the Royal Society of Chemistry. This grant means we will be able to further develop our unique Encapsulated Nano-droplet Crystallisation technology.
Indicatrix is excited to announce that we have begun to search for next year’s undergraduate industrial placement student. Details can be found following the link below, and applications will be accepted until 4th Feb 2022
We’re excited to announce that this year we’ll be taking on an industrial placement student to work alongside our team through the academic year 2021/22. If you’d be interested in applying for the post then please see the attached job description.
Dr Mike Probert gave a talk highlighting the impacts of technologies operating at the nano-scale as part of the Pint of Science festival. Specifically he breaks down the benefits of ENaCt within the realms of pharmaceutical development.
The development of our ground breaking high-throughput Encapsulated Nanoscale Crystallization technology (ENaCt) will continue via a Newcastle University-based PhD CASE award with AstraZeneca. The aim of the project is to ‘control’ the solid form of new drug-like molecules to have improved bioavailability and physical properties.
More details can be found on the Newcastle University website:
Indicatrix CEO Dr Michael Hall delivering a presentation on Encapsulated Nanodroplet Crystallisation experiments for the Winter 2020 ABX Antibiotic Discovery meeting held at the University of Plymouth. The talk covers the general concept of ENaCt as well as it’s development and features some nice examples which have been worked on by the team at Newcastle University.
The impact of Indicatrix’s patent pending ENaCt technology on the potential enchantment of drug development pipelines is highlighted in a new article in the European Pharmaceutical Review “New Technique to Grow Crystals from Nanoscale Droplets Developed”.